Back

Empagliflozin significantly reduces circulating markers of endothelial dysfunction in Ischemia with Non-Obstructive Coronary Arteries (INOCA) and coronary microvascular dysfunction: a pilot trial

30 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in women around the world Cardiovascular Disease in Women ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Odayme Quesada

The Christ Hospital Health Network, Cincinnati (United States of America)

7 More presentations in this session

Presentation thumbnail
Sex differences in health status trajectories among Chinese patients with angina pectoris: insights from the GREAT registry study
Professor X. Du (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Sex disparities in ischaemic heart disease mortality in South Asia: a global burden of disease 2021 analysis
Ms T. Rahaman (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Impact of atorvastatin on serum oestradiol and estrone concentrations in postmenopausal women with chronic coronary artery disease: a randomized trial.
Miss N. Faria (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Coronary artery disease-related sudden cardiac arrest in women
Doctor O. Weizman (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Bridging the gender gap in TAVI: real-world evidence from a single-centre study
Doctor R. Batista Louro (Evora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in women around the world

The Event

Event poster

ESC Congress 2025

30 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin significantly reduces the capacity of sera to induce endothelial dysfunction in Ischemia Non-Obstructive Coronary Arteries (INOCA): EMbArk phase II pilot trial
thumbnail
Congress Session
Diagnosis and treatment of microvascular and epicardial coronary artery disease
thumbnail
Congress Presentation
Multiple co-existing endotypes in a patient with ischaemia and non-obstructive coronary artery disease – approach to diagnosis and stratified therapy.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources